Myeloproliferative neoplasm screening: Difference between revisions
No edit summary |
Shyam Patel (talk | contribs) No edit summary |
||
(4 intermediate revisions by 3 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Myeloproliferative disease}} | {{Myeloproliferative disease}} | ||
{{CMG}} {{AE}} {{MJK}} | {{CMG}} {{AE}} {{MJK}} {{shyam}} | ||
==Overview== | ==Overview== | ||
There are currently no guidelines for screening for myeloproliferative neoplasm. Monitoring of the complete blood count is done routinely. | |||
==Screening== | ==Screening== | ||
There are currently no guidelines for screening for myeloproliferative neoplasm. Routine monitoring of complete blood count (CBC) once yearly is sufficient for screening for hematologic diseases in general.<ref name="pmid28028026">{{cite journal| author=Rumi E, Cazzola M| title=Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. | journal=Blood | year= 2017 | volume= 129 | issue= 6 | pages= 680-692 | pmid=28028026 | doi=10.1182/blood-2016-10-695957 | pmc=5335805 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28028026 }} </ref> | |||
==References== | ==References== | ||
Line 19: | Line 18: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] |
Latest revision as of 05:55, 28 June 2018
Myeloproliferative Neoplasm Microchapters |
Differentiating myeloproliferative neoplasm from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Myeloproliferative neoplasm screening On the Web |
American Roentgen Ray Society Images of Myeloproliferative neoplasm screening |
Directions to Hospitals Treating Myeloproliferative neoplasm |
Risk calculators and risk factors for Myeloproliferative neoplasm screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2] Shyam Patel [3]
Overview
There are currently no guidelines for screening for myeloproliferative neoplasm. Monitoring of the complete blood count is done routinely.
Screening
There are currently no guidelines for screening for myeloproliferative neoplasm. Routine monitoring of complete blood count (CBC) once yearly is sufficient for screening for hematologic diseases in general.[1]
References
- ↑ Rumi E, Cazzola M (2017). "Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms". Blood. 129 (6): 680–692. doi:10.1182/blood-2016-10-695957. PMC 5335805. PMID 28028026.